- Home
- KNSA
as 03-28-2025 4:00pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 1.6B | IPO Year: | 2018 |
| Target Price: | $37.17 | AVG Volume (30 days): | 634.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.56 - $28.15 | Next Earning Date: | 04-22-2025 |
| Revenue: | $423,239,000 | Revenue Growth: | 56.60% |
| Revenue Growth (this year): | 37.21% | Revenue Growth (next year): | 1.38% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Mar 20 '25 | Sell | $23.11 | 15,944 | $368,465.84 | 23,382 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Mar 16 '25 | Sell | $23.10 | 20,343 | $469,923.30 | 23,382 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Mar 12 '25 | Sell | $22.25 | 36,372 | $809,277.00 | 23,382 | |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Mar 12 '25 | Sell | $22.45 | 9,051 | $203,194.95 | 26,528 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Feb 10 '25 | Sell | $19.57 | 14,000 | $273,980.00 | 81,975 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Jan 13 '25 | Sell | $18.60 | 14,000 | $255,413.15 | 81,975 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%
Motley Fool
15 days ago
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
MT Newswires
16 days ago
Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target
Insider Monkey
22 days ago
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now?
Zacks
24 days ago
Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock
Zacks
25 days ago
Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?
Zacks
25 days ago
Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?
Insider Monkey
a month ago
Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now?
Compare KNSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.